公开(公告)号：US20230302031A1

公开(公告)日：2023-09-28

申请号：US17928352

申请日：2021-06-01

申请人： Institut Gustave-Roussy

发明人： Jean-Luc PERFETTINI ,  Deborah LECUYER ,  Desiree TANNOUS ,  Awatef ALLOUCH ,  Oliver DELELIS ,  Frederic SUBRA

IPC分类号： A61K31/7048 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61K31/196 ,  A61K31/64 ,  A61K31/191

CPC分类号： A61K31/7048 ,  A61K45/06 ,  A61P11/00 ,  A61P31/14 ,  A61K31/196 ,  A61K31/64 ,  A61K31/191

摘要： The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.